IHL-675A: Advancing Towards Innovative Arthritis Solutions,

Mark Bleackley, PhD, discusses the upcoming phase 2 trial of IHL-675A designed to explore arthritis treatment through dual-drug comparison, promising global expansion, and its impact on patients’ pain relief.

Related Keywords

Australia , Mark Bleackley , Incannex Healthcare , Chief Scientific Officer , Incannex Healthcare Limited , Routine Assessment , Patient Index Data ,